Demonstrates enhanced antitumor responses in multiple tumor models using a novel dual-permeable gel.
Local administration of drug-encapsulated gels has shown promise for cancer treatment. However, intratumoral drug diffusion is hindered by the dense extracellular matrix. Herein, a versatile skin- and tumor-dual-permeable manganese-dimethyl sulfoxide (Mn-DMSO) gel platform, with a nanofiber structure (MnSO 4 ·2H 2 O·C 2 H 6 SO as suggested by single-crystal structure), for cancer chemoimmunotherapy is introduced, which can be locally applied either through peritumoral injection for multiple tumor types or transdermal delivery for superficial tumors. This gel has a thermoresponsive sol–gel phase transition at 37 °C and intrinsic tumoricidal and cGAS-STING activation capabilities. Importantly, in addition to being a drug reservoir and taking advantage of the tissue penetration ability of DMSO, the gel is tumor-permeable and achieves a 2.5-fold enhancement in tumor penetration of drugs compared with free ones. In multiple tumor models, a peritumorally injected Mn-DMSO gel coencapsulated with a chemodrug (gemcitabine) and an immune agonist (R848) effectively triggers cGAS-STING-mediated local and systemic antitumor responses. Furthermore, we demonstrate that topical application of the R848- and gemcitabine-coloaded Mn-DMSO gel on the skin surface enables noninvasive transdermal delivery of chemo-/immunodrugs into tumors, thereby inhibiting tumor growth and metastasis in a melanoma model. Our findings highlight a gel platform that supports both injectable and topical administration for enhanced cancer therapy.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: